Loading
institutionsInstitution
Amsterdam UMC / Cancer Center Amsterdam
The merged Amsterdam university hospitals (AMC and VUmc), whose Cancer Center Amsterdam is one of the largest academic cancer research programmes in the Netherlands.
Also called: AMCVUmcCancer Center Amsterdam
Overview
Amsterdam UMC was formed by the 2018 merger of the Academic Medical Center (University of Amsterdam) and VU University Medical Center (Vrije Universiteit). Cancer Center Amsterdam is its research and care institute for oncology, spanning medical oncology, haematology, radiotherapy, surgical oncology and imaging on two campuses. Strengths include pancreatic and hepatobiliary surgery, colorectal cancer biology and organoids, lymphoma and leukaemia, imaging and radiotherapy, and cancer immunology, and the centre works alongside the Netherlands Cancer Institute within the Amsterdam cancer ecosystem.
Location
Amsterdam, NL
Type
hospital · University of Amsterdam / Vrije Universiteit Amsterdam
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#349 · 18 points (0 Newsweek + 0 NCI + 18 from 9 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Amsterdam University Medical Centers, including child institutions. 2,104 works · 25,115 citations · 86% open access · 9% clinical trials · 5% reviews.
Oncology works per year
5132022
4922023
4592024
3912025
2492026
Most works
- Marc G. Besselink390 works
- Bas Groot Koerkamp232 works
- Olivier R. Busch144 works
- Ignace H. J. T. de Hingh113 works
- Hjalmar C. van Santvoort106 works
- Evelien Dekker101 works
- Casper H.J. van Eijck94 works
- Geert Kazemier93 works
- Martijn W.J. Stommel92 works
- Bert A. Bonsing86 works
Most cited
- Pancreatic and hepatobiliary surgery
- Colorectal cancer biology
- Haematology
- Imaging and radiotherapy
Hans van Goudoever
Voorzitter (Chair) of the Raad van Bestuur, Amsterdam UMC
Academic medicineHospital governancePaediatrics
Chair of the executive board of Amsterdam UMC, the merged university medical centre whose research institute Cancer Center Amsterdam brings together the city's cancer research and care.
Marc G. Besselink
Professor of Pancreatic and Hepatobiliary Surgery, Amsterdam UMC
Pancreatic surgeryNeoadjuvant therapyMinimally invasive pancreatectomy
Dutch surgeon who leads the PREOPANC trials testing chemotherapy or chemoradiation before pancreatic cancer surgery.
rctThe Lancet Oncology 202532 citations
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
Together with NORPACT-1 this left the neoadjuvant question for resectable disease open: FOLFIRINOX before surgery is not proven superior to alternatives, and the comparison against upfront surgery with adjuvant modified FOLFIRINOX is what PREOPANC-3 and Alliance A021806 are running.
rctJournal of Clinical Oncology 2020changed practice786 citations
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
The trial that made neoadjuvant treatment standard for borderline resectable disease and opened the still unresolved question for resectable disease, which PREOPANC-2, NORPACT-1, PREOPANC-3 and Alliance A021806 inherited.
Similar pages
- TrialPREOPANC-1
Shares Dutch Pancreatic Cancer Group, Marc G. Besselink, Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial, Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
- Key paperPREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer
Shares Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial, Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial, Pancreatic ductal adenocarcinoma.
- TrialNetherlands Cancer Institute HIPEC trial
Shares COLOPEC, Netherlands Cancer Institute (NKI-AvL), Colorectal cancer.
- InstitutionUniversity of Wisconsin Carbone Cancer Center
Shares ViewRay (MRIdian), MR-guided adaptive radiotherapy, Colorectal cancer.
- InstitutionUMC Utrecht Cancer Center
Shares Netherlands Cancer Institute (NKI-AvL), MR-guided adaptive radiotherapy, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- Key paperNORPACT-1: neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer
Shares Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial, Pancreatic ductal adenocarcinoma.
- IdeaChemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed
Shares Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial, Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial, Pancreatic ductal adenocarcinoma.
- IdeaPre-consented cohorts that can be randomised to future trials (TwiCs)
Shares Netherlands Cancer Institute (NKI-AvL), Colorectal cancer.
cancers
technologies
companies
institutions
trials
people
key papers
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trialPreoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial